ArticleAdvances in laboratory medicine2025
Evaluating the research parameters available on the Sysmex
Article in Advances in laboratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by peripheral blood cytopenias, cellular dysplasia and risk for progression into acute leukemia. Recent studies reveal that some research parameters available on Sysmex XN-1000 Methods: Seventy-five patients older than 60 years with anemia, leukopenia or thrombocytopenia, without vitamin B12 and folate deficiency or hematological diseases underwent testing with the Sysmex XN-1000 analyzer. Results: Dysplasia was confirmed in 32 % of patients, with significant differences in Neu-GI, PDW and IPF count between the groups of patients with and without dysplasia. Neu-GI was the parameter with the highest predictive value (AUC=0.98), with such value not increasing significantly after the addition of PDW or PIF. A Neu-GI value≤146ch predicts dysplasia with a positive predictive value=90 %. Conclusions: Neu-GI is the parameter most strongly associated with dysplasia. A Neu-GI value≤146ch indicates a high probability of dysplasia and supports indication for a blood smear review. Additionally, values>152ch indicate a low probability of dysplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.